The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 24, 2006

Filed:

Apr. 21, 2000
Applicants:

Mohammad R. Marzabadi, Ridgewood, NJ (US);

Wai C. Wong, Hamden, CT (US);

Stewart A. Noble, Wheeling, IL (US);

Manesh N. Desai, Nutley, NJ (US);

Inventors:

Mohammad R. Marzabadi, Ridgewood, NJ (US);

Wai C. Wong, Hamden, CT (US);

Stewart A. Noble, Wheeling, IL (US);

Manesh N. Desai, Nutley, NJ (US);

Assignee:

H. Lundbick A/S, Volby-Copenhagen, DK;

Attorney:
Int. Cl.
CPC ...
C07D 513/04 (2006.01); C07D 513/22 (2006.01); A61K 31/381 (2006.01); A61P 3/04 (2006.01);
U.S. Cl.
CPC ...
Abstract

This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.


Find Patent Forward Citations

Loading…